2010 Diary Dates! Conference & Exhibition: 27-28 October 2010 Pre-Conference Workshops: 26 October 2010 Post-Conference Workshops: 29 October 2010
Implementation of QbD for biologics - an update on case study and pilot initiatives and current industry practices Over the last few years, the implementation path for application of Quality by Design to biologic pharmaceutical development has become increasingly clearer, due in large part to collaborative industry initiatives and the encouragement of international health authorities. This talk will overview the role of the A-Mab case study, well as the FDA’s biotech pilot program and other Health Authority interactions, in driving implementation of QbD in the biologics arena. Dr Lynne Krummen, Senior. Director, Pharma Technical Regulatory, Genentech, Inc., USA
RNA interference is being applied in bioprocessing to optimize and improve the production of biologics. Using this approach, multiple key pathways can be potently targeted individually or in combination. Such treatments can be transiently applied to suspension cell cultures grown at scale in bioprocessors, and can result in significant improvements in cell performance impacting both product yield and quality. Dr Anthony Rossomando, Senior Director, Biotherapeutics/Bioprocessing, Alnylam Biotherapeutics, USA For your Exclusive copy of this keynote interview, click HERE
Quite interesting in current technology information (Genhelix Spain)
Very interesting and focusing (ROUICM)
Instantaneous Industrial Nice Picture = The event contains all the relevant information I need to know today. (Merck Serono Biodevelopment)
In general interesting (CEVEC Pharmaceuticals)
Well conducted and useful conference. Good speakers and nice location. (DSM Biologics BV)
A clever interface between basic science and production. (Medicago inc)
A resumé of the most important items in biotech forums. (Genhelix Spain)
Very good overview of current industry practices and areas of interest. (Pfizer Inc)
Large and diverse conference, maybe too large. Excellent, driven speakers. (Toxicon)
Good event in a nice city. (NNE Pharmaplan)
Very high quality presentations. A clear picture of QbD for biotechs. (Sanofi-Aventis)
It was ok, but I took a number of useful notes. (ETH Zurich)
Workshops were good and informative (Teva Pharmaceuticals)
Interesting, my first EU conference. (Sandoz)
Interesting speakers, well arranged, good networking opportunities. (GE Healthcare)
Excellent organization, good selection of speakers. Some focus on drug product regulatory and quality would be appreciated. Nice venue facility. (Kuros Biosurgery AG)
A great opportunity to network and meet up with colleagues. (Biopharm Services)
Good networking opportunities and useful for viewing future Bioproduction trends. (Laboratorios Hipra SA)
Very informative conference in a beautiful city. (Centocor)
Excellent in depth coverage of subject areas. (Domantis Ltd)
Good organisation and good opportunity for networking. Interesting technical presentations. (GlaxoSmithKline Biologicals)
Good networking, content level useful, some conferences better than other (Sealed Air)
Excellent event! The possibility to switch between four conferences made the attendance most valuable for me! (Suppremol)
The conference is perfectly organised, enabling highly efficient exchange among the participants. (Novartis Biologics)
Very useful and well organised. (GlaxoSmithKline R&D)
Good condensed update on the state and trends of the Bioproduction Business. (Merck Serono)
Focused – good technical and process content. (LFB Biotechnologies)
This was an interesting opportunity to speak to a variety of QbD experts and to hear what we should incorporate in our Masters programme. (De Montfort University)